Efficacy and Safety of Androgen Receptor Pathway-Targeted Therapies in AR-Positive Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis

Breast cancer is not a single disease but a collection of different conditions that happen to share a name. Doctors classify these conditions by looking at the specific proteins on the surface of the cancer cells, which act like switches that tell the tumor how to grow. One particularly aggressive type, known as triple-negative breast cancer, lacks three of the most common switches: estrogen, progesterone, and HER2. Because it lacks these targets, standard hormone therapies that work for many other breast cancers simply do not work for this type, leaving doctors with fewer tools to fight it. However, researchers have noticed that a small subset of these triple-negative tumors still carries a different switch called the androgen receptor. This receptor usually responds to male hormones, and scientists have long wondered if blocking it could slow down or stop these specific tumors, offering a new path for patients who have run out of options.

A team of researchers set out to find the answer by gathering every available study that tested drugs designed to block this androgen receptor in patients with triple-negative breast cancer. They looked at eleven different clinical trials involving hundreds of patients, ranging from early experiments to larger, more structured studies. Their goal was to see if these drugs could shrink tumors or, perhaps more importantly, keep the disease from getting worse for a meaningful amount of time. The researchers focused on two main questions: how often did the tumors actually shrink, and how often did the treatment successfully hold the disease in check for at least sixteen weeks?

The results revealed a surprising pattern that challenges how doctors usually measure success in cancer treatment. When looking at the standard definition of a positive response—where a tumor shrinks significantly—the drugs performed poorly. Only about five out of every one hundred patients saw their tumors shrink enough to be counted as a success. If a doctor were judging these drugs solely on tumor shrinkage, they might conclude the treatment does not work. However, when the researchers looked at a different measure called the clinical benefit rate, which counts patients whose tumors either shrank or simply stopped growing for a sustained period, the picture changed. In this broader view, nearly one out of every three patients experienced a meaningful benefit, with their disease held in a stable state for at least sixteen weeks.

This difference in results makes sense when you consider how these specific tumors behave. The subset of triple-negative breast cancer that carries the androgen receptor tends to grow slowly and steadily, rather than exploding with rapid, chaotic division. The drugs used in these studies work by turning off the signal that tells the cancer cells to divide, effectively putting them in a state of suspended animation. This is why the tumors rarely disappear completely or shrink dramatically, but they also rarely grow larger. The treatment acts more like a brake on a car than a hammer; it stops the vehicle from moving forward without necessarily destroying the engine. This explains why the drugs were so effective at maintaining stability for many patients, even though they failed to produce dramatic shrinkage.

The researchers also examined the safety of these treatments and found that they were generally well-tolerated. The most common side effects were fatigue, nausea, and hot flashes, which are manageable for many people. When the drugs were combined with other medications to boost their power, the side effects became more intense, particularly regarding blood cell counts, but the overall profile remained acceptable. The study also highlighted a significant hurdle for the future: the way doctors currently identify which patients have this specific type of cancer is not precise enough. Different studies used different thresholds to decide who was eligible, and this lack of a standard definition likely diluted the results. Some patients included in the trials may not have actually had tumors driven by the androgen receptor, which would explain why the overall success rates were not higher.

Ultimately, this review suggests that androgen receptor-targeted therapies offer a real, albeit modest, lifeline for a specific group of patients with triple-negative breast cancer. These drugs are unlikely to be the first choice for someone needing immediate, rapid tumor reduction, but they provide a valuable option for maintaining quality of life and keeping the disease under control for those whose tumors are slow-growing. The findings point toward a future where treatment is tailored more precisely, using better tests to identify the patients who will truly benefit from this approach, and where these drugs are used as part of a combination strategy to overcome the cancer's ability to adapt. The work confirms that while the path forward is complex, there is a distinct biological logic to why these drugs work the way they do, offering a new perspective on how to fight a difficult disease.